Literature DB >> 9362335

Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells.

J S Levine1, J S Koh, V Triaca, W Lieberthal.   

Abstract

Lysophosphatidic acid (LPA) is the smallest and structurally simplest of all glycerophospholipids. LPA is a normal constituent of serum and binds with high affinity to albumin while retaining its biological activity. The effects of LPA are pleiotropic and range from mitogenesis to stress fiber formation. In this report, we demonstrate two novel functions for LPA. LPA acts as a survival factor to inhibit apoptosis of primary cultures of mouse renal proximal tubular (MPT) cells. LPA also acts as a potent mitogen for MPT cells. The ability of LPA to act as both a survival factor and a mitogen is mediated by the lipid kinase phosphatidylinositol 3-kinase (PI3K), since these activities were completely blocked by wortmannin or LY-294002, two structurally dissimilar inhibitors of PI3K. The identification of LPA as a proliferative and anti-apoptotic factor suggests a potential role for this lipid mediator during the injury and/or recovery phases following tubular damage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9362335     DOI: 10.1152/ajprenal.1997.273.4.F575

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  16 in total

1.  Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model.

Authors:  Ming-Zhi Zhang; Xin Wang; Haichun Yang; Agnes B Fogo; Brian J Murphy; Robert Kaltenbach; Peter Cheng; Bradley Zinker; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2017-07-24       Impact factor: 10.121

2.  Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist.

Authors:  James E East; Karen M Carter; Perry C Kennedy; Nancy A Schulte; Myron L Toews; Kevin R Lynch; Timothy L Macdonald
Journal:  Medchemcomm       Date:  2011-03-03       Impact factor: 3.597

3.  Hypoalbuminemia: a risk factor for acute kidney injury development and progression to chronic kidney disease in critically ill patients.

Authors:  Min Shao; Shengyu Wang; Praveen Kolumam Parameswaran
Journal:  Int Urol Nephrol       Date:  2016-11-05       Impact factor: 2.370

4.  Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase.

Authors:  X Fang; S Yu; R LaPushin; Y Lu; T Furui; L Z Penn; D Stokoe; J R Erickson; R C Bast; G B Mills
Journal:  Biochem J       Date:  2000-11-15       Impact factor: 3.857

5.  Hen egg yolk and white contain high amounts of lysophosphatidic acids, growth factor-like lipids: distinct molecular species compositions.

Authors:  S Nakane; A Tokumura; K Waku; T Sugiura
Journal:  Lipids       Date:  2001-04       Impact factor: 1.880

Review 6.  Lysophosphatidic acid and renal fibrosis.

Authors:  Jean-Philippe Pradère; Julien Gonzalez; Julie Klein; Philippe Valet; Sandra Grès; David Salant; Jean-Loup Bascands; Jean-Sébastien Saulnier-Blache; Joost P Schanstra
Journal:  Biochim Biophys Acta       Date:  2008-04-11

7.  Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells.

Authors:  Yutaka Hasegawa; Mandi Murph; Shuangxing Yu; Gabor Tigyi; Gordon B Mills
Journal:  Mol Oncol       Date:  2008-06       Impact factor: 6.603

8.  Lysophosphatidic acid prevents renal ischemia-reperfusion injury by inhibition of apoptosis and complement activation.

Authors:  Bart de Vries; Robert A Matthijsen; Annemarie A J H M van Bijnen; Tim G A M Wolfs; Wim A Buurman
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

9.  Vectorial secretion of CTGF as a cell-type specific response to LPA and TGF-β in human tubular epithelial cells.

Authors:  Jonathan Zuehlke; Astrid Ebenau; Bettina Krueger; Margarete Goppelt-Struebe
Journal:  Cell Commun Signal       Date:  2012-09-02       Impact factor: 5.712

10.  Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials.

Authors:  Christian J Wiedermann; Stefan Dunzendorfer; Luigi U Gaioni; Francesco Zaraca; Michael Joannidis
Journal:  Crit Care       Date:  2010-10-28       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.